The vessel wall: A forgotten player in post thrombotic syndrome

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 681-692

  DeRoo, Scott ^a   Deatrick, K Barry ^a   Henke, Peter K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cell matrix interactions; Deep vein thrombosis; Inflammation; Matrix metalloproteinases

Indexed keywords

CHEMOKINE RECEPTOR CCR2; DOXYCYCLINE; FIBROBLAST GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONTELUKAST; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANTICOAGULATION; BLOOD VESSEL WALL; CHRONIC VEIN INSUFFICIENCY; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; HUMAN; NONHUMAN; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RECANALIZATION; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER;

ANTICOAGULANTS; CYTOKINES; DRUG THERAPY; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASES; MYOCYTES, SMOOTH MUSCLE; SYNDROME; VEINS; VENOUS THROMBOSIS; WOUND HEALING;

EID: 77958114364     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0183     Document Type: Review

References (139)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.
2. Bergan JJ, Schmid-Schonbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006; 355: 488-498.
3. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
4. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. Ann Surg 2004; 239: 118-126. (Pubitemid 38176381)
5. Tsai S, Dubovoy A, Wainess R, et al. Severe chronic venous insufficiency: magnitude of the problem and consequences. Ann Vasc Surg 2005; 19: 705-711. (Pubitemid 41218952)
6. Patterson BO, Hinchliffe R, Loftus IM, et al. Indications for catheter-directed thrombolysis in the management of acute proximal deep venous thrombosis. Arterioscler Thromb Vasc Biol 2010; 30: 669-674.
7. Gasparis AP, Awadallah M, Meisner RJ, et al. Recurrent popliteal vein aneurysm. J Vasc Surg 2010; 51: 453-457.
8. Kahn SR. How I treat postthrombotic syndrome. Blood 2009; 114: 4624-4631.
9. Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 2005; 42: 140-148.
10. Henke PK, Pearce CG, Moaveni DM, et al. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. J Immunol 2006; 177: 3388-3397.
11. Henke PK, Wakefield T. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res 2009; 123 (Suppl 4): S72-78.
12. Roumen-Klappe EM, Janssen MC, Van Rossum J, et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost 2009; 7: 582-587.
13. Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb Haemost 2009; 101: 505-512.
14. Varma MR, Varga AJ, Knipp BS, et al. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg 2003; 38: 1090-1098.
15. Henke PK, Varma MR, Moaveni DK, et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. Thromb Haemost 2007; 98: 1045-1055.
16. Sevitt S. The mechanisms of canalisation in deep vein thrombosis. J Pathol 1973; 110: 153-165.
17. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 258-268.
18. Henke PK, Varma MR, Deatrick KB, et al. Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization. Thromb Haemost 2006; 95: 272-281.
19. Wang Y, Bai Y, Qin L, et al. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res 2007; 101: 560-569. (Pubitemid 351325873)
20. Yoshida T, Gan Q, Shang Y, et al. Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters. Am J Physiol Cell Physiol 2007; 292: C886-895.
21. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801. (Pubitemid 38823766)
22. Aguilera CM, George SJ, Johnson JL, et al. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res 2003; 58: 679-688.
23. Thyberg J, Hultgardh-Nilsson A. Fibronectin and the basement membrane components laminin and collagen type IV influence the phenotypic properties of subcultured rat aortic smooth muscle cells differently. Cell Tissue Res 1994; 276: 263-271. (Pubitemid 24125474)
24. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839. (Pubitemid 36542523)
25. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
26. Zhang F, Tsai S, Kato K, et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J Biol Chem 2009; 284: 17564-17574.
27. Schecter AD, Berman AB, Taubman MB. Chemokine receptors in vascular smooth muscle. Microcirculation 2003; 10: 265-272. (Pubitemid 39004254)
28. Seino Y, Ikeda U, Takahashi M, et al. Expression of monocyte chemoattractant protein-1 in vascular tissue. Cytokine 1995; 7: 575-579.
29. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg 1999; 30: 894-899.
30. Porreca E, Di Febbo C, Reale M, et al. Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. J Vasc Res 1997; 34: 58-65. (Pubitemid 27105915)
31. Viedt C, Vogel J, Athanasiou T, et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol 2002; 22: 914-920. (Pubitemid 34655217)
32. Ikeda U, Okada K, Ishikawa S, et al. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells. Am J Physiol 1995; 268: H1021-1026.
33. Hayes IM, Jordan NJ, Towers S, et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998; 18: 397-403. (Pubitemid 28125634)
34. Egashira K, Zhao Q, Kataoka C, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90: 1167-1172. (Pubitemid 34786901)
35. Roque M, Kim WJ, Gazdoin M, et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2002; 22: 554-559. (Pubitemid 34408733)
36. Schober A, Zernecke A, Liehn EA, et al. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 2004; 95: 1125-1133. (Pubitemid 39557900)
37. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730-737.
38. Diao Y, Guthrie S, Xia SL, et al. Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts. Am J Pathol 2008; 172: 839-848. (Pubitemid 351354555)
39. Caplice NM, Bunch TJ, Stalboerger PG, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci USA 2003; 100: 4754-4759.
40. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, et al. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74: 196-206.
41. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116: 217-224.
42. Sajid M, Hu Z, Guo H, Li H, Stouffer GA. Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury. J Investig Med 2001; 49: 398-406. (Pubitemid 32777003)
43. McCaffrey TA, Consigli S, Du B, et al. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest 1995; 96: 2667-2675.
44. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-1904.
45. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-982. (Pubitemid 34655226)
46. Kobayashi K, Yokote K, Fujimoto M, et al. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ Res 2005; 96: 904-912. (Pubitemid 40604975)
47. Adam PJ, Regan CP, Hautmann MB, et al. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo. J Biol Chem 2000; 275: 37798-37806.
48. Hautmann MB, Madsen CS, Owens GK. A transforming growth factor beta (TGFbeta) control element drives TGFbeta-induced stimulation of smooth muscle alpha-actin gene expression in concert with two CArG elements. J Biol Chem 1997; 272: 10948-10956.
49. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001; 81: 999-1030. (Pubitemid 32606665)
50. Henke PK, Varma MR, Moaveni DK, et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. Thromb Haemost 2007; 98: 1045-1055.
51. Lindner V, Lappi DA, Baird A, et al. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991; 68: 106-113.
52. Jackson CL, Reidy MA. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration. Am J Pathol 1993; 143: 1024-1031. (Pubitemid 24070543)
53. Rauch BH, Millette E, Kenagy RD, et al. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res 2004; 94: 340-345. (Pubitemid 38240725)
54. Millette E, Rauch BH, Kenagy RD, et al. Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc Med 2006; 16: 25-28. (Pubitemid 43012038)
55. Chen PY, Simons M, Friesel R. FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor beta-mediated regulation of vascular smooth muscle marker gene expression. J Biol Chem 2009; 284: 15980-15992.
56. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316. (Pubitemid 29473317)
57. Raines EW, Bowen-Pope DF, Ross R. Platelet-Derived Growth Factor. Vol 95 pt. I. Heidelberg: Springer-Verlad; 1990.
58. Nilsson J, Sjolund M, Palmberg L, et al. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1985; 82: 4418-4422. (Pubitemid 15234245)
59. Shimokado K, Raines EW, Madtes DK, et al. A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell 1985; 43: 277-286. (Pubitemid 16199714)
60. Kaplan DR, Chao FC, Stiles CD, et al. Platelet alpha granules contain a growth factor for fibroblasts. Blood 1979; 53: 1043-1052.
61. Corjay MH, Blank RS, Owens GK. Platelet-derived growth factor-induced destabilization of smooth muscle alpha-actin mRNA. J Cell Physiol 1990; 145: 391-397. (Pubitemid 120027376)
62. Regan CP, Adam PJ, Madsen CS, et al. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J Clin Invest 2000; 106: 1139-1147.
63. Yang Z, Oemar BS, Carrel T, et al. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 1998; 97: 181-187. (Pubitemid 28124676)
64. Yoshida T, Kaestner KH, Owens GK. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ Res 2008; 102: 1548-1557.
65. Tanner FC, Meier P, Greutert H, et al. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000; 101: 1982-1989. (Pubitemid 30225281)
66. Blank RS, Owens GK. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells. J Cell Physiol 1990; 142: 635-642.
67. Kumar MS, Hendrix JA, Johnson AD, et al. Smooth muscle alpha-actin gene requires two E-boxes for proper expression in vivo and is a target of class I basic helix-loop-helix proteins. Circ Res 2003; 92: 840-847.
68. Liu Y, Sinha S, Owens G. A transforming growth factor-beta control element required for SM alpha-actin expression in vivo also partially mediates GKLF-dependent transcriptional repression. J Biol Chem 2003; 278: 48004-48011. (Pubitemid 37523250)
69. Deaton RA, Gan Q, Owens GK. Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle. Am J Physiol Heart Circ Physiol 2009; 296: H1027-1037.
70. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 369-375. (Pubitemid 38197592)
71. Hultgardh-Nilsson A, Durbeej M. Role of the extracellular matrix and its receptors in smooth muscle cell function: implications in vascular development and disease. Curr Opin Lipidol 2007; 18: 540-545. (Pubitemid 47462207)
72. Hedin U, Roy J, Tran PK, et al. Control of smooth muscle cell proliferation - the role of the basement membrane. Thromb Haemost. 1999; 82 (Suppl 1): 23-26. (Pubitemid 30093626)
73. Koyama H, Raines EW, Bornfeldt KE, et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996; 87: 1069-1078. (Pubitemid 26427990)
74. Alberts B JA, Lewis J, Raff M, et al. Molecular Biology of the Cell. 5 ed. New York: Garland Science; 2008.
75. Snow AD, Bolender RP, Wight TN, et al. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137: 313-330.
76. Fukai N, Kenagy RD, Chen L, et al. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009; 29: 1356-1362.
77. Myers DD, Jr., Henke PK, Bedard PW, et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 2006; 44: 625-632.
78. See-Tho K, Harris EJ, Jr. Thrombosis with outflow obstruction delays thrombolysis and results in chronic wall thickening of rat veins. J Vasc Surg 1998; 28: 115-123. (Pubitemid 28347643)
79. Sansilvestri-Morel P, Rupin A, Jaisson S, et al. Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation 2002; 106: 479-483. (Pubitemid 34803694)
80. Sansilvestri-Morel P, Rupin A, Badier-Commander C, et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 2001; 38: 560-568. (Pubitemid 33151596)
81. Hedin U, Bottger BA, Forsberg E, et al. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. J Cell Biol 1988; 107: 307-319.
82. Chiang HY, Korshunov VA, Serour A, et al. Fibronectin is an important regulator of flow-induced vascular remodeling. Arterioscler Thromb Vasc Biol 2009; 29: 1074-1079.
83. Taillefer R. Radiolabeled peptides in the detection of deep venous thrombosis. Semin Nucl Med 2001; 31: 102-123. (Pubitemid 32298296)
84. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 2008; 6: 158-172.
85. Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 2527-2532.
86. Ma C, Chegini N. Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-beta1. Mol Hum Reprod 1999; 5: 950-954. (Pubitemid 29470320)
87. Gurjar MV, DeLeon J, Sharma RV, et al. Mechanism of inhibition of matrix metalloproteinase- 9 induction by NO in vascular smooth muscle cells. J Appl Physiol 2001; 91: 1380-1386. (Pubitemid 32803936)
88. Gurjar MV, Deleon J, Sharma RV, et al. Role of reactive oxygen species in IL-1 beta-stimulated sustained ERK activation and MMP-9 induction. Am J Physiol Heart Circ Physiol 2001; 281: H2568-2574.
89. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-376.
90. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189. (Pubitemid 24187750)
91. Turner NA, Hall KT, Ball SG, et al. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis 2007; 193: 36-43.
92. Rotmans JI, Velema E, Verhagen HJ, et al. Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg 2004; 39: 432-439. (Pubitemid 38174330)
93. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78: 38-43. (Pubitemid 26004118)
94. Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res 2009; 81: 178-186.
95. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006; 108: 1441-1450. (Pubitemid 44316107)
96. Tu G, Xu W, Huang H, et al. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 2008; 15: 1388-1395. (Pubitemid 351997789)
97. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36: 1-12.
98. Sood V, Luke C, Miller E, et al. Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline. Ann Vasc Surg 2010; 24: 233-241.
99. Singh I, Burnand KG, Collins M, et al. Failure of thrombus to resolve in urokinase- type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107: 869-875. (Pubitemid 36241046)
100. Henke PK. Plasmin and matrix metalloproteinase system in deep venous thrombosis resolution. Vascular 2007; 15: 366-371.
101. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
102. Carmeliet P, Bouche A, De Clercq C, et al. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995; 748: 367-382.
103. Carmeliet P, Moons L, Herbert JM, et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81: 829-839. (Pubitemid 27467218)
104. Lijnen HR, Van Hoef B, Lupu F, et al. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 1035-1045. (Pubitemid 28323587)
105. Roztocil E, Nicholl SM, Davies MG. Mechanisms of kringle fragment of urokinase- induced vascular smooth muscle cell migration. J Surg Res 2007; 141: 83-90. (Pubitemid 46898451)
106. Roztocil E, Nicholl SM, Galaria, II, et al. Plasmin-induced smooth muscle cell proliferation requires epidermal growth factor activation through an extracellular pathway. Surgery 2005; 138: 180-186. (Pubitemid 41253799)
107. Nicholl SM, Roztocil E, Davies MG. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor. J Vasc Surg 2005; 41: 672-681. (Pubitemid 40637668)
108. Bakken AM, Protack CD, Roztocil E, et al. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism. J Vasc Surg 2009; 49: 1296-1303.
109. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387-391.
110. Otsuka G, Stempien-Otero A, Frutkin AD, et al. Mechanisms of TGF-beta1-induced intimal growth: plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ Res 2007; 100: 1300-1307. (Pubitemid 46742920)
111. Otsuka G, Agah R, Frutkin AD, et al. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 2006; 26: 737-743. (Pubitemid 43732145)
112. Peng L, Bhatia N, Parker AC, et al. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 2002; 22: 934-939. (Pubitemid 34655220)
113. de Waard V, Arkenbout EK, Carmeliet P, et al. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol 2002; 22: 1978-1983. (Pubitemid 36025202)
114. Kouri FM, Queisser MA, Konigshoff M, et al. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. Int J Biochem Cell Biol 2008; 40: 1872-1882.
115. Otsuka G, Stempien-Otero A, Frutkin AD, et al. Mechanisms of TGF-{beta}1-Induced Intimal Growth. Plasminogen-Independent Activities of Plasminogen Activator Inhibitor-1 and Heterogeneous Origin of Intimal Cells. Circ Res 2007; 100: 1300-1307.
116. Suzuki J, Ogawa M, Muto S, et al. The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. Expert Opin Ther Targets 2008; 12: 783-794. (Pubitemid 352003320)
117. Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor- 1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180-3191. (Pubitemid 27500124)
118. Bond M, Wu YJ, Sala-Newby GB, et al. Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo. Cardiovasc Res 2008; 80: 290-298.
119. Alevriadou BR. CAMs and Rho small GTPases: gatekeepers for leukocyte transendothelial migration. Focus on "VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration". Am J Physiol Cell Physiol 2003; 285: C250-252.
120. Diebold I, Djordjevic T, Hess J, et al. Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription. Thromb Haemost 2008; 100: 1021-1028.
121. Patterson C, Stouffer GA, Madamanchi N, et al. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88: 987-997. (Pubitemid 34137110)
122. Liu MW, Roubin GS, King SB, 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-1387.
123. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777. (Pubitemid 19124139)
124. Moaveni DK, Lynch EM, Luke C, et al. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin. J Vasc Surg 2008; 47: 616-624. (Pubitemid 351258279)
125. Largiader T, Eto M, Payeli SK, et al. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A. J Cardiovasc Pharmacol 2008; 52: 369-374.
126. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 1999; 18: 578-585. (Pubitemid 29057242)
127. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522: 177-185.
128. Modarai B, Burnand KG, Sawyer B, et al. Endothelial progenitor cells are recruited into resolving venous thrombi. Circulation 2005; 111: 2645-2653. (Pubitemid 40740865)
129. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996; 32: 687-698.
130. Corselli M, Chien-Wen C, Crisan M, et al. Perivascular Ancestors of Adult Multipotent Stem Cells. Arterioscl Thromb Vasc Biol 2010; 30: 1104-1109.
131. Dore-Duffy P, Owen C, Balabanov R, et al. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 2000; 60: 55-69. (Pubitemid 30456828)
132. Juchem G, Weiss DR, Gansera B, et al. Pericytes in the macrovascular intima: possible physiological and pathogenetic impact. Am J Physiol Heart Circ Physiol 2010; 298: H754-770.
133. Wakefield TW, Myers D, Henke P. Role of selectins and fibrinolysis in VTE. Thrombosis Res 2009: S35-S40.
134. Myers D, Wrobleski S, Londy F, et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Haemost 2002; 87: 374-382. (Pubitemid 34232476)
135. Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. Rev Cardiovasc Med 2002; 3 (Suppl 2): S61-67.
136. Glynn RJ, Danielson E, Fonseca FA, et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360: 1851-1861.
137. Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol 2005; 3: 1-9. (Pubitemid 40089524)
138. Kahn SR. How I manage the post thrombotic syndrome. Blood 2009; 114: 4624-4631.
139. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg 2009; 250: 219-228.